Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of CD40.HIVRI.Env HIV Vaccine
NCT04842682Phase 1Completed
- Sponsor
- ANRS
- Start
- Mar 2021
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CD40.HIVRI.Env in human immunodeficiency virus infection (HIV) (9 arms), sponsored by ANRS. Primary endpoint: Proportion of participants without any grade 3 or 4 adverse event. Started Mar 2021; status: completed.
02
Drugs
CD40.HIVRI.Env
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04842682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842682.